IDEXX Laboratories, Inc. (IDXX)
Quantitative Summary
DeterministicAt 41.5x earnings — a 36% discount to the sector average of 65.2x — IDXX is in the lower valuation range. Financial health metrics are strong: Piotroski 7/9, Altman Z 20.8 (above 3.0 safe zone threshold). DCF fair value of $182 implies 68% downside based on model assumptions.
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe fundamental economics of IDEXX Laboratories exhibit exceptional capital efficiency, underscored by an ROIC-WACC spread of +33.8%, which signals robust value creation relative to the cost of equity. This high return is driven primarily by superior operating leverage rather than financial engineering; specifically, a net margin of 24.6% and asset turnover of 1.28x contribute significantly to an ROE of 66.0%, while the moderate equity multiplier of 2.09x suggests limited reliance on debt amplification. Qualitative risk metrics further reinforce this stability, with a Piotroski F-Score of 7/9 indicating strong financial health and a Beneish M-Score of -2.46 effectively ruling out earnings manipulation risks, although an Altman Z-Score of 21.6 remains comfortably within the safe zone for solvency.
Despite these operational strengths, current valuation metrics suggest the market is pricing in aggressive future performance that may not align with discounted cash flow models. The stock trades at a forward P/E of 43.5x, substantially exceeding the sector average of 30.8x, implying significant expectations for continued acceleration beyond the reported 10.4% revenue growth rate. A DCF analysis incorporating an implied ten-year FCF growth assumption of 32.5% yields a fair value of $184, representing a -67.2% discount to current levels; however, this wide divergence highlights that any miss in the high-growth trajectory could materially compress multiples given the premium valuation multiple already embedded in the share price.
From a factor investing perspective, the security displays distinct characteristics with a substantial Fama-French alpha of 33.64%, driven by robust profitability (RMW: 0.349) despite a negative value tilt (HML: -0.353). While insider activity over the last ninety days shows net selling totaling $29,862,141, potentially signaling caution from management regarding near-term targets or liquidity needs, the underlying quality metrics remain intact. The combination of high profitability and significant insider outflows creates a complex risk-reward profile where strong fundamentals coexist with elevated valuation sensitivity and active shareholder distribution.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
DCF Sandbox
Interactive5-year two-stage DCF. Terminal growth 3%. Default sliders match the pre-computed base case. Drag to explore scenarios. Not investment advice.
The growth rate the market implicitly expects over the next 10 years to justify today's price. Compare with historical growth of 10% YoY revenue.
Sensitivity Matrix
| TG ↓ / WACC → | 13.2% | 15.2% | 17.2% |
|---|---|---|---|
| 2% | $207 | $171 | $146 |
| 3% | $222 | $182 | $153 |
| 4% | $241 | $194 | $161 |
Center = base case. Green = >10% upside, Red = >10% downside vs $550.82.
Pre-computed DCF: WACC=15.2%, terminal growth 3%. Fair value $182 (-68.3%). Not investment advice.
Valuation Context
Currently trading 13% below its 5-year average P/E of 49.7x.
Price Chart with Moving Averages
Technical Setup
AI GeneratedIDXX is currently trading at $553.07 within the healthcare sector, presenting a technical snapshot that requires further context regarding its moving averages to fully assess trend alignment. Without specific data on whether the price sits above or below key exponential or simple moving averages, it remains unclear if the asset is in an established uptrend or experiencing pullback dynamics relative to its recent history. The absence of this positional information limits a definitive conclusion about the strength and direction of the medium-to-long term trajectory at this precise moment. Regarding short-term momentum indicators, the Relative Strength Index (RSI) status is not provided in the current dataset, preventing an analysis of whether immediate buying or selling pressure might be building toward overbought or oversold conditions. A complete technical picture would integrate these missing components to determine if recent price action reflects sustained acceleration or potential exhaustion. Consequently, while the stock holds a specific valuation point, the interplay between its current level and dynamic averages, alongside unstated momentum readings, creates an incomplete narrative regarding immediate directional bias. Ultimately, the available figures isolate the absolute price but omit the relational metrics necessary to gauge trend integrity or short-term velocity. Investors must await confirmation on moving average positions and RSI levels before forming a comprehensive view of whether the current market structure supports continued appreciation or faces resistance from underlying technical forces.
Quant Health Deep Dive
Profitability & Value Creation
DuPont Analysis — ROE Decomposition
Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.
Balance Sheet Health
Insider Activity (Last 90 Days)
Open-market buys vs sells by company insiders. Source: yfinance.
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Risk Profile
Sharpe = risk-adjusted return (higher is better). Max drawdown = largest peak-to-trough decline. 1,200+ trading days.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fama-French 5-Factor Exposure
Academic factor model decomposition — what's really driving this stock's returns.
Fama-French 5-Factor Model. Data: Kenneth French Data Library. Regression over 3 years of daily returns.
Fundamentals
Passive Flow Attribution
ETF Draft EffectWhen investors buy or sell ETFs like IHI or XHE, the fund manager is mechanically forced to buy or sell IDXX shares regardless of IDEXX Laboratories, Inc.'s individual fundamentals. We estimate $7.8B of passive capital is structurally linked to IDXX through 8 tracked ETFs. This substantial passive exposure means that ETF inflows and outflows — not company fundamentals — can dominate daily volume on this stock.
Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.
ETF Contagion Visualizer
Simulate a price drop in IDEXX Laboratories, Inc. to visualize passive redemption contagion across ETFs and collateral stocks.
If IDEXX Laboratories, Inc. (IDXX) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies Abbott Laboratories (ABT) as the most exposed collateral stock, sharing 2 ETFs with IDXX. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 31 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
IDXX Ownership Dynamics
Passive funds hold 1 in every 6 IDXX shares, reducing daily market volatility.
IDEXX Laboratories, Inc. (IDXX) exerts notable gravity on the passive index market, currently representing 4.7% of the IHI (IHI) and 1.6% of the XHE (XHE). Across 30 tracked ETFs, approximately 14M shares (17.6% of float) are held by passive funds and rarely trade on the open market. This level of passive ownership means index rebalances can create outsized volume events.
ETFs with Highest IDXX Exposure
Float lock-up computed from 30 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
IDXX Institutional Volume Profile
252-day volume distribution by price level. The Point of Control (POC) marks — the price where the most institutional volume transacted — an implicit support/resistance floor.
The highest-volume price zone for IDEXX Laboratories, Inc. over the past year sits near $643.90 (14% of 252-day volume). The current price of $550.82 sits 14.5% below the POC — suggesting potential mean-reversion upside if institutional demand reasserts at this level. The highly concentrated volume profile (14% at POC) indicates strong consensus on fair value — institutional participants have repeatedly transacted near this price.
Volume Profile computed from 252 trading days of OHLCV data. Volume allocated to price bins proportionally based on daily high-low range. Not investment advice.
IDXX Capital Efficiency
How efficiently does IDEXX Laboratories, Inc. convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
IDEXX Laboratories, Inc. converts 69% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag. The positive ROIC-WACC spread of 33.7% confirms that reinvested capital creates shareholder value.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-05-12 | 3,957 | $532.00 | $2.1M |
| 2026-05-04 | 6 | $567.46 | $3,404.76 |
| 2026-04-29 | 389 | $568.30 | $221,068.7 |
| 2026-04-27 | 8 | $565.93 | $4,527.44 |
| 2026-04-24 | 13,026 | $560.93 | $7.3M |
| 2026-04-20 | 33 | $589.25 | $19,445.25 |
| 2026-04-07 | 46 | $577.44 | $26,562.24 |
| 2026-04-01 | 1 | $561.89 | $561.89 |
| 2026-03-25 | 8 | $570.21 | $4,561.68 |
| 2026-03-24 | 1 | $578.51 | $578.51 |
| 2026-03-23 | 46 | $577.26 | $26,553.96 |
| 2026-03-05 | 154 | $648.70 | $99,899.8 |
| 2026-02-25 | 14 | $649.23 | $9,089.22 |
| 2026-02-24 | 4,296 | $623.13 | $2.7M |
| 2026-02-12 | 1 | $648.73 | $648.73 |
| 2026-02-10 | 62 | $639.79 | $39,666.98 |
| 2026-02-05 | 2,460 | $642.94 | $1.6M |
| 2026-02-04 | 3,686 | $632.56 | $2.3M |
| 2026-01-20 | 200 | $715.37 | $143,074 |
| 2026-01-15 | 1 | $710.48 | $710.48 |
| 2026-01-09 | 85 | $712.39 | $60,553.15 |
| 2026-01-07 | 1 | $706.83 | $706.83 |
| 2026-01-02 | 3,166 | $676.53 | $2.1M |
| 2025-12-30 | 52 | $687.89 | $35,770.28 |
| 2025-12-24 | 729 | $682.31 | $497,403.99 |
| 2025-12-22 | 400 | $700.34 | $280,136 |
| 2025-12-18 | 27 | $695.60 | $18,781.2 |
| 2025-12-11 | 6 | $701.83 | $4,210.98 |
| 2025-12-09 | 131 | $706.65 | $92,571.15 |
| 2025-12-04 | 49 | $725.93 | $35,570.57 |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
Price Correlations
Statistical correlation of daily returns with other stocks. High correlations indicate stocks that move together; negative correlations can offer diversification.
| Peer | 252-Day (1Y) | 126-Day (6M) | Direction |
|---|---|---|---|
| WTGXX | NaN | NaN | |
| VISN | 0.658 | 0.068 | Moderate |
| RMD | 0.444 | 0.349 | Moderate |
| BEN | 0.397 | 0.360 | Moderate |
| HSIC | 0.388 | 0.367 | Moderate |
| VRTPX | 0.388 | 0.326 | Moderate |
| ALGN | 0.371 | 0.487 | Moderate |
| ZTS | 0.363 | 0.332 | Moderate |
| MTD | 0.363 | 0.385 | Moderate |
| IR | 0.363 | 0.305 | Moderate |
Pearson correlation of daily log returns. 252d ≈ 1 trading year. Computed from price history. Not investment advice.
Compare IDXX to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: 2026-06-02.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.